LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
RLAY
Relay Therapeutics, Inc.
There isn't enough reported data to score RLAY yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RLAY Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
RLAY's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RLAY PE Valuation
RLAY has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
RLAY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect RLAY's revenue to decline, with its earnings and profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over RLAY on earnings quality, reporting a profit while its opponent remains loss making.
RLAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.50 | +$0.22 |
| Q2 2026 | -$1.56 | +$0.36 |
| Q1 2026 | -$1.56 | +$0.64 |
| Q4 2025 | -$1.61 | +$0.75 |
| Q3 2025 | -$1.72 | +$0.90 |
| Q2 2025 | -$1.92 | +$0.61 |
| Q1 2025 | -$2.20 | +$0.45 |
| Q4 2024 | -$2.36 | +$0.45 |
RLAY is still losing money, but far less than before: $1.50 per share over the past year, against $3.92 at its worst in early 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over RLAY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over RLAY on profitability, with a higher operating margin.
RLAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $350K | -48% |
| Q1 2026 | $3M | -61% |
| Q1 2025 | $7.7M | -23% |
| Q1 2024 | $10M | +4328% |
| Q3 2023 | $25.2M | +7226% |
| Q2 2023 | $119K | -67% |
| Q1 2023 | $226K | -46% |
| Q4 2022 | $253K | -99% |
RLAY's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -25950% | -14599 points |
| Q1 2026 | -2620% | -1515 points |
| Q4 2025 | -866% | N/A |
| Q2 2025 | -11351% | N/A |
| Q1 2025 | -1105% | -202 points |
| Q1 2024 | -903% | +43866 points |
| Q3 2023 | -292% | +24677 points |
| Q2 2023 | -89118% | -67800 points |
RLAY's operating margin was −25950% last quarter, down 24845 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with RLAY at down 7.9%.
RLAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$63.9M | -$1.8M |
| Q4 2025 | -$44.9M | +$13M |
| Q3 2025 | -$62.1M | +$13.2M |
| Q2 2025 | -$55.3M | +$10.6M |
| Q1 2025 | -$73.6M | -$21.5M |
| Q4 2024 | -$57.9M | +$31.4M |
| Q3 2024 | -$75.3M | +$677K |
| Q2 2024 | -$65.8M | +$4.3M |
RLAY has burned cash in almost every quarter: −$226M over the past year, against −$273M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over RLAY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RLAY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8% | +16.3M shares |
| 1 year | +27% | +46.8M shares |
| 3 years | +79% | +96.9M shares |
| 5 years | +136% | +126M shares |
RLAY has 219M diluted shares, up 27% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RLAY Net Leverage
RLAY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RLAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.9 | Neutral |
| Stochastic | 43.1 | Neutral |
RLAY's weekly RSI is 55 (neutral) and its Stochastic is 43 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RLAY PE vs Healthcare Sector
RLAY has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over RLAY on trend strength, trading above more of its moving averages.
RLAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.0 | 0.6% above |
| 20 week MA | $18.7 | 3.4% below |
| 50 week MA | $14.2 | 27% above |
| 100 week MA | $9.17 | 97% above |
| 200 week MA | $9.50 | 90% above |
RLAY's trend is mixed: it's above four of its five weekly moving averages, and 90% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
RLAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.0 | $46.9 | +6.6% |
| 2021 | $46.9 | $33.4 | -29% |
| 2022 | $33.4 | $14.6 | -56% |
| 2023 | $14.6 | $11.0 | -25% |
| 2024 | $11.0 | $4.36 | -60% |
| 2025 | $4.36 | $8.56 | +96% |
| 2026 YTD | $8.56 | $18.1 | +111% |
RLAY has the edge over LLY on returns for 2026, with the stronger performance.